Patents by Inventor Katherine E. Keating
Katherine E. Keating has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11254986Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: GrantFiled: July 21, 2016Date of Patent: February 22, 2022Assignee: Almac Diagnostics Services LimitedInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Patent number: 11091809Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: December 3, 2013Date of Patent: August 17, 2021Assignee: Almac Diagnostic Services LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Publication number: 20190316203Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: ApplicationFiled: July 21, 2016Publication date: October 17, 2019Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Patent number: 10378066Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: February 7, 2017Date of Patent: August 13, 2019Assignee: Almac Diagnostic Services LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 10280468Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: GrantFiled: February 9, 2015Date of Patent: May 7, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
-
Patent number: 10260097Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: June 4, 2012Date of Patent: April 16, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10214777Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: August 13, 2015Date of Patent: February 26, 2019Assignee: Almac Diagnostics LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20170198360Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: February 7, 2017Publication date: July 13, 2017Inventors: Jude O'DONNELL, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 9677140Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: October 7, 2013Date of Patent: June 13, 2017Assignee: ALMAC DIAGONOSTICS LIMITEDInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 9670547Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: September 15, 2011Date of Patent: June 6, 2017Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20170073761Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: ApplicationFiled: February 9, 2015Publication date: March 16, 2017Inventors: Denis Paul HARKIN, Richard KENNEDY, Katherine E. KEATING, Andrena MCCAVIGAN, Laura A. HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
-
Publication number: 20160060705Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: August 13, 2015Publication date: March 3, 2016Applicant: Almac Diagnostics LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20160002732Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: December 3, 2013Publication date: January 7, 2016Inventors: Dennis Paul HARKIN, Fionnuala PATTERSON, Claire TRINDER, Eamonn J. O'BRIEN, Caroline MICHIE, Charlie GOURLEY, Laura A. HILL, Katherine E. KEATING, Jude O'DONNELL, Max BYLESJO, Steve DEHARO, Vitali PROUTSKI, Richard KENNEDY, Timothy DAVISON, Andreas WINTER, Andrena MCCAVIGAN
-
Publication number: 20140342924Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: June 4, 2012Publication date: November 20, 2014Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Dennis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Publication number: 20140051591Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: September 15, 2011Publication date: February 20, 2014Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hills, Katherine E. Keating, Timothy Davison, Vitali Proutski, Dennis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Publication number: 20140031260Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: October 7, 2013Publication date: January 30, 2014Inventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard